Skip to content

Author

A. Sud

We have 3 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

The interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination, and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.

Maclean C. Sellars, Jessica A. Frank, Bohoon Shim et al. · 0 citations
Review Open access Jul 2026

Moving beyond the neutral-Darwinian dichotomy to inform precision oncology.

It is argued that tumour evolution is not a binary state, but a dynamic continuum shaped by genetic and non-genetic heterogeneity, spatial constraints, microenvironmental pressures and therapeutic bottlenecks, which will align these models with therapeutic decision-making in precision oncology.

A. Sud, R. Houlston · 0 citations
Jul 2026

Tertiary lymphoid structures harbour stem-like tumour-specific T cells

Tertiary lymphoid structures are reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immunotherapies, and are found to be reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immune pressure.

Alexander B. Afeyan, Adi Nagler, Chloe R. Tu et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.